BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10797296)

  • 1. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
    Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
    Int J Cancer; 2000 Jun; 86(5):718-24. PubMed ID: 10797296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
    Barth S; Huhn M; Wels W; Diehl V; Engert A
    Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
    Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
    Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice.
    Pfister K; Wittig BM; Jüngling B; Ecker KW; Barth S; Huhn M; Sasse S; Engert A; Mueller-Molaian I; Diehl V; Zeitz M; Stallmach A
    Int J Colorectal Dis; 2002 Mar; 17(2):77-84. PubMed ID: 12014425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
    Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
    Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
    Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P
    Int J Cancer; 1991 Sep; 49(3):450-6. PubMed ID: 1917143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.
    Winkler U; Gottstein C; Schön G; Kapp U; Wolf J; Hansmann ML; Bohlen H; Thorpe P; Diehl V; Engert A
    Blood; 1994 Jan; 83(2):466-75. PubMed ID: 8286745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).
    Matthey B; Engert A; Barth S
    Int J Mol Med; 2000 Nov; 6(5):509-14. PubMed ID: 11029515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
    Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
    Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
    Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
    Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
    Engert A; Diehl V; Schnell R; Radszuhn A; Hatwig MT; Drillich S; Schön G; Bohlen H; Tesch H; Hansmann ML; Barth S; Schindler J; Ghetie V; Uhr J; Vitetta E
    Blood; 1997 Jan; 89(2):403-10. PubMed ID: 9002941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.
    Schnell R; Borchmann P; Staak JO; Schindler J; Ghetie V; Vitetta ES; Engert A
    Ann Oncol; 2003 May; 14(5):729-36. PubMed ID: 12702527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
    Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
    Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.
    Schnell R; Vitetta E; Schindler J; Borchmann P; Barth S; Ghetie V; Hell K; Drillich S; Diehl V; Engert A
    Leukemia; 2000 Jan; 14(1):129-35. PubMed ID: 10637488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
    Bruell D; Stöcker M; Huhn M; Redding N; Küpper M; Schumacher P; Paetz A; Bruns CJ; Haisma HJ; Fischer R; Finnern R; Barth S
    Int J Oncol; 2003 Oct; 23(4):1179-86. PubMed ID: 12964002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
    Schnell R; Katouzi AA; Linnartz C; Schoen G; Drillich S; Hansmann ML; Schiefer D; Barth S; Zangemeister-Wittke U; Stahel RA; Diehl V; Engert A
    Int J Cancer; 1996 May; 66(4):526-31. PubMed ID: 8635869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.